CASI Current Deferred Revenue vs Net Tangible Assets Analysis

CASI Stock

USD 1.48 0.06 4.23%

CASI Pharmaceuticals financial indicator trend analysis is way more than just evaluating CASI Pharmaceuticals prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether CASI Pharmaceuticals is a good investment. Please check the relationship between CASI Pharmaceuticals Current Deferred Revenue and its Net Tangible Assets accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CASI Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

For more detail on how to invest in CASI Stock please use our How to Invest in CASI Pharmaceuticals guide.

Current Deferred Revenue vs Net Tangible Assets

Current Deferred Revenue vs Net Tangible Assets Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of CASI Pharmaceuticals Current Deferred Revenue account and Net Tangible Assets. At this time, the significance of the direction appears to have strong relationship.

The correlation between CASI Pharmaceuticals' Current Deferred Revenue and Net Tangible Assets is 0.77. Overlapping area represents the amount of variation of Current Deferred Revenue that can explain the historical movement of Net Tangible Assets in the same time period over historical financial statements of CASI Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of CASI Pharmaceuticals' Current Deferred Revenue and Net Tangible Assets is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Current Deferred Revenue of CASI Pharmaceuticals are associated (or correlated) with its Net Tangible Assets. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Tangible Assets has no effect on the direction of Current Deferred Revenue i.e., CASI Pharmaceuticals' Current Deferred Revenue and Net Tangible Assets go up and down completely randomly.

Correlation Coefficient

0.77

Relationship Direction	Positive
Relationship Strength	Significant

View All Relationships

Current Deferred Revenue

Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.

Net Tangible Assets

The total assets of a company minus any intangible assets such as patents, copyrights, and goodwill; it represents the physical assets of a company.

Most indicators from CASI Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into CASI Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CASI Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

For more detail on how to invest in CASI Stock please use our How to Invest in CASI Pharmaceuticals guide.As of now, CASI Pharmaceuticals' Selling General Administrative is increasing as compared to previous years. Tax Provision is expected to grow at the current pace this year, while Sales General And Administrative To Revenue is projected to decrease to 0.78.

	2022	2023	2024	2025 (projected)
Research Development	16.0M	9.9M	8.9M	10.7M
Depreciation And Amortization	2.4M	3.7M	2.3M	2.4M

Research Development Depreciation And Amortization

CASI Pharmaceuticals fundamental ratios Correlations

	Common Stock Shares Outstanding	Total Assets	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Cash And Short Term Investments	Common Stock Total Equity	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Common Stock	Short Long Term Debt Total	Other Current Liab	Non Currrent Assets Other	Net Receivables	Non Current Liabilities Total	Other Current Assets	Short Term Debt	Other Assets	Long Term Debt
Common Stock Shares Outstanding		0.73	0.86	0.38	0.88	-0.14	-0.86	0.79	0.39	0.59	0.56	1.0	0.73	0.88	0.95	0.73	0.12	0.67	0.84	0.68	0.85	0.48	-0.14	0.56	0.18	0.94
Total Assets	0.73		0.32	0.89	0.77	-0.7	-0.6	0.8	0.82	0.89	0.89	0.74	0.75	0.39	0.6	0.94	0.67	0.06	0.34	0.73	0.37	0.16	-0.04	-0.02	0.44	0.82
Total Current Liabilities	0.86	0.32		-0.07	0.67	0.28	-0.71	0.5	-0.02	0.22	0.15	0.85	0.42	0.91	0.88	0.34	-0.27	0.85	0.9	0.4	0.93	0.45	-0.07	0.85	-0.03	0.76
Total Stockholder Equity	0.38	0.89	-0.07		0.43	-0.91	-0.29	0.52	0.94	0.76	0.93	0.4	0.55	-0.05	0.19	0.86	0.82	-0.27	-0.05	0.5	-0.05	-0.18	0.04	-0.29	0.39	0.53
Property Plant And Equipment Net	0.88	0.77	0.67	0.43		-0.12	-0.7	0.88	0.29	0.82	0.45	0.86	0.66	0.75	0.89	0.62	0.28	0.41	0.72	0.89	0.79	0.52	-0.08	0.29	0.23	0.84
Net Debt	-0.14	-0.7	0.28	-0.91	-0.12		0.11	-0.26	-0.95	-0.51	-0.88	-0.16	-0.41	0.31	0.07	-0.74	-0.75	0.5	0.27	-0.24	0.29	0.46	-0.02	0.4	-0.34	-0.28
Retained Earnings	-0.86	-0.6	-0.71	-0.29	-0.7	0.11		-0.66	-0.33	-0.45	-0.47	-0.86	-0.88	-0.78	-0.79	-0.63	-0.09	-0.59	-0.63	-0.57	-0.67	-0.55	0.59	-0.47	-0.15	-0.76
Accounts Payable	0.79	0.8	0.5	0.52	0.88	-0.26	-0.66		0.43	0.79	0.55	0.79	0.69	0.62	0.8	0.69	0.39	0.34	0.56	0.74	0.55	0.41	-0.13	0.11	0.27	0.79
Cash	0.39	0.82	-0.02	0.94	0.29	-0.95	-0.33	0.43		0.57	0.97	0.42	0.57	-0.04	0.17	0.89	0.7	-0.22	-0.03	0.34	-0.06	-0.3	0.0	-0.19	0.34	0.52
Non Current Assets Total	0.59	0.89	0.22	0.76	0.82	-0.51	-0.45	0.79	0.57		0.65	0.59	0.6	0.32	0.53	0.68	0.74	-0.06	0.23	0.8	0.33	0.21	-0.05	-0.08	0.48	0.67
Cash And Short Term Investments	0.56	0.89	0.15	0.93	0.45	-0.88	-0.47	0.55	0.97	0.65		0.58	0.62	0.15	0.35	0.95	0.67	-0.05	0.14	0.43	0.12	-0.12	-0.03	-0.07	0.39	0.66
Common Stock Total Equity	1.0	0.74	0.85	0.4	0.86	-0.16	-0.86	0.79	0.42	0.59	0.58		0.73	0.87	0.94	0.75	0.14	0.66	0.83	0.66	0.84	0.47	-0.13	0.56	0.21	0.94
Other Stockholder Equity	0.73	0.75	0.42	0.55	0.66	-0.41	-0.88	0.69	0.57	0.6	0.62	0.73		0.53	0.62	0.76	0.35	0.28	0.41	0.64	0.43	0.41	-0.53	0.12	0.24	0.69
Total Liab	0.88	0.39	0.91	-0.05	0.75	0.31	-0.78	0.62	-0.04	0.32	0.15	0.87	0.53		0.92	0.38	-0.23	0.86	0.91	0.5	0.92	0.73	-0.14	0.66	0.09	0.76
Property Plant And Equipment Gross	0.95	0.6	0.88	0.19	0.89	0.07	-0.79	0.8	0.17	0.53	0.35	0.94	0.62	0.92		0.57	-0.07	0.7	0.9	0.64	0.93	0.61	-0.07	0.54	0.17	0.89
Total Current Assets	0.73	0.94	0.34	0.86	0.62	-0.74	-0.63	0.69	0.89	0.68	0.95	0.75	0.76	0.38	0.57		0.52	0.15	0.39	0.57	0.35	0.11	-0.03	0.03	0.34	0.81
Common Stock	0.12	0.67	-0.27	0.82	0.28	-0.75	-0.09	0.39	0.7	0.74	0.67	0.14	0.35	-0.23	-0.07	0.52		-0.42	-0.37	0.39	-0.3	-0.28	-0.11	-0.32	0.48	0.21
Short Long Term Debt Total	0.67	0.06	0.85	-0.27	0.41	0.5	-0.59	0.34	-0.22	-0.06	-0.05	0.66	0.28	0.86	0.7	0.15	-0.42		0.78	0.15	0.73	0.59	-0.08	0.79	-0.14	0.54
Other Current Liab	0.84	0.34	0.9	-0.05	0.72	0.27	-0.63	0.56	-0.03	0.23	0.14	0.83	0.41	0.91	0.9	0.39	-0.37	0.78		0.54	0.96	0.58	0.08	0.6	-0.12	0.72
Non Currrent Assets Other	0.68	0.73	0.4	0.5	0.89	-0.24	-0.57	0.74	0.34	0.8	0.43	0.66	0.64	0.5	0.64	0.57	0.39	0.15	0.54		0.57	0.39	-0.12	0.01	0.0	0.62
Net Receivables	0.85	0.37	0.93	-0.05	0.79	0.29	-0.67	0.55	-0.06	0.33	0.12	0.84	0.43	0.92	0.93	0.35	-0.3	0.73	0.96	0.57		0.59	0.0	0.67	0.01	0.75
Non Current Liabilities Total	0.48	0.16	0.45	-0.18	0.52	0.46	-0.55	0.41	-0.3	0.21	-0.12	0.47	0.41	0.73	0.61	0.11	-0.28	0.59	0.58	0.39	0.59		-0.29	0.18	0.17	0.37
Other Current Assets	-0.14	-0.04	-0.07	0.04	-0.08	-0.02	0.59	-0.13	0.0	-0.05	-0.03	-0.13	-0.53	-0.14	-0.07	-0.03	-0.11	-0.08	0.08	-0.12	0.0	-0.29		-0.09	-0.07	0.03
Short Term Debt	0.56	-0.02	0.85	-0.29	0.29	0.4	-0.47	0.11	-0.19	-0.08	-0.07	0.56	0.12	0.66	0.54	0.03	-0.32	0.79	0.6	0.01	0.67	0.18	-0.09		-0.07	0.45
Other Assets	0.18	0.44	-0.03	0.39	0.23	-0.34	-0.15	0.27	0.34	0.48	0.39	0.21	0.24	0.09	0.17	0.34	0.48	-0.14	-0.12	0.0	0.01	0.17	-0.07	-0.07		0.25
Long Term Debt	0.94	0.82	0.76	0.53	0.84	-0.28	-0.76	0.79	0.52	0.67	0.66	0.94	0.69	0.76	0.89	0.81	0.21	0.54	0.72	0.62	0.75	0.37	0.03	0.45	0.25

Click cells to compare fundamentals

CASI Pharmaceuticals Account Relationship Matchups

CASI Pharmaceuticals fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Common Stock Shares Outstanding	11.0M	13.6M	13.6M	13.4M	15.3M	16.1M
Total Assets	127.7M	138.3M	96.2M	75.3M	53.7M	49.2M
Total Current Liabilities	8.0M	13.2M	17.0M	16.7M	36.5M	38.3M
Total Stockholder Equity	81.5M	84.5M	44.6M	24.2M	1.9M	1.8M
Property Plant And Equipment Net	10.8M	21.8M	13.2M	11.6M	11.4M	11.9M
Net Debt	(55.8M)	(36.5M)	(45.8M)	4.2M	8.7M	9.1M
Retained Earnings	(570.5M)	(605.6M)	(637.2M)	(660.8M)	(700.1M)	(665.1M)
Accounts Payable	3.7M	4.8M	3.3M	4.4M	2.7M	2.7M
Cash	57.1M	38.7M	47.1M	17.1M	13.5M	12.8M
Non Current Assets Total	53.7M	76.3M	22.8M	15.9M	13.9M	9.9M
Cash And Short Term Investments	66.4M	48.6M	51.3M	30.8M	16.1M	32.1M
Common Stock Total Equity	953.7K	979K	1.2M	1.4M	1.6M	1.7M
Liabilities And Stockholders Equity	127.7M	138.3M	96.2M	75.3M	53.7M	49.2M
Other Stockholder Equity	650.2M	686.8M	682.4M	686.2M	703.7M	396.2M
Total Liab	24.2M	30.3M	29.3M	51.1M	51.8M	54.4M
Property Plant And Equipment Gross	10.8M	12.7M	15.5M	16.3M	17.1M	17.9M
Total Current Assets	74.0M	62.0M	73.4M	59.3M	39.6M	39.3M
Accumulated Other Comprehensive Income	589K	2.0M	(703K)	(1.2M)	(1.8M)	(1.9M)
Common Stock	979K	1.2M	1.4M	1K	2K	1.9K
Short Long Term Debt Total	1.3M	2.2M	1.3M	21.2M	22.1M	23.2M
Other Current Liab	1.6M	6.7M	10.8M	11.1M	11.6M	12.2M
Non Currrent Assets Other	299K	2.2M	1.1M	766K	587K	331.0K
Net Receivables	4.6M	9.8M	13.0M	10.1M	15.3M	16.1M
Non Current Liabilities Total	16.2M	17.2M	12.3M	34.4M	15.4M	16.1M
Other Current Assets	1.7M	1.7M	3.0M	2.6M	2.9M	2.3M
Short Term Debt	2.2M	1.1M	868K	728K	19.6M	20.6M
Other Assets	504K	38.4M	2.2M	197K	226.6K	215.2K
Property Plant Equipment	1.8M	985K	10.8M	22.0M	25.3M	26.6M
Short Term Investments	9.3M	9.9M	4.2M	13.7M	2.6M	4.8M
Inventory	1.4M	1.9M	6.1M	15.9M	5.3M	2.8M
Intangible Assets	13.2M	12.2M	1.1M	1.8M	238K	226.1K
Net Tangible Assets	109.5M	93.7M	68.3M	72.3M	83.1M	50.3M

Currently Active Assets on Macroaxis

USOI	Credit Suisse X Links
ULTY	Tidal Trust II
CONY	YieldMax N Option
BCAT	BlackRock Capital Allocation
PDI	Pimco Dynamic Income

When determining whether CASI Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of CASI Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Casi Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Casi Pharmaceuticals Stock:

How To Invest In CASI

Details

Is CASI Stock a good investment?

Details

What is CASI Pharmaceuticals' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CASI Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

For more detail on how to invest in CASI Stock please use our How to Invest in CASI Pharmaceuticals guide.

You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CASI Pharmaceuticals. If investors know CASI will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CASI Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(2.54)

Revenue Per Share

1.977

Quarterly Revenue Growth

0.83

Return On Assets

(0.51)

Return On Equity

(10.95)

The market value of CASI Pharmaceuticals is measured differently than its book value, which is the value of CASI that is recorded on the company's balance sheet. Investors also form their own opinion of CASI Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is CASI Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CASI Pharmaceuticals' market value can be influenced by many factors that don't directly affect CASI Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between CASI Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if CASI Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CASI Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2025 Macroaxis LLC

CASI Current Deferred Revenue vs Net Tangible Assets Analysis

Current Deferred Revenue vs Net Tangible Assets

Current Deferred Revenue vs Net Tangible Assets Correlation Analysis

Correlation Coefficient

Current Deferred Revenue

Net Tangible Assets

CASI Pharmaceuticals fundamental ratios Correlations

CASI Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

CASI Pharmaceuticals fundamental ratios Accounts

Currently Active Assets on Macroaxis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Common Stock Total Equity	+ 1.0	Common Stock Shares Outstanding
Cash And Short Term Investments	+ 0.97	Cash
Net Receivables	+ 0.96	Other Current Liab
Property Plant And Equipment Gross	+ 0.95	Common Stock Shares Outstanding
Total Current Assets	+ 0.95	Cash And Short Term Investments
Long Term Debt	+ 0.94	Common Stock Shares Outstanding

Cash	- 0.95	Net Debt
Net Debt	- 0.91	Total Stockholder Equity
Other Stockholder Equity	- 0.88	Retained Earnings
Cash And Short Term Investments	- 0.88	Net Debt
Common Stock Total Equity	- 0.86	Retained Earnings
Retained Earnings	- 0.86	Common Stock Shares Outstanding